Paying users zone. Data is covered by .
Get to Eli Lilly & Co. for $19.99, or
get to entire website for at least 3 months from $49.99.
Eli Lilly & Co. (LLY)
Price to FCFE (P/FCFE)
Free Cash Flow to Equity (FCFE)
Eli Lilly & Co., FCFE calculation
USD $ in thousands
|FCFE||Free cash flow to equity is the cash flow available to Eli Lilly & Co.’s equity holders after all operating expenses, interest, and principal payments have been paid and necessary investments in working and fixed capital have been made.||Eli Lilly & Co.’s FCFE increased from 2016 to 2017 but then declined significantly from 2017 to 2018.|
Price to FCFE Ratio, Current
Eli Lilly & Co., current P/FCFE calculation, comparison to benchmarks
|No. shares of common stock outstanding|
|Selected Financial Data (USD $)|
|Free cash flow to equity (FCFE) (in thousands)|
|FCFE per share|
|Current share price (P)|
|Bristol-Myers Squibb Co.|
|Gilead Sciences Inc.|
|Johnson & Johnson|
|Merck & Co. Inc.|
|Regeneron Pharmaceuticals Inc.|
|Pharmaceuticals & Biotechnology|
Based on: 10-K (filing date: 2019-02-19).
If company P/FCFE is lower then the P/FCFE of benchmark then company is relatively undervalued.
Otherwise, if company P/FCFE is higher then the P/FCFE of benchmark then company is relatively overvalued.
Price to FCFE Ratio, Historical
Eli Lilly & Co., historical P/FCFE calculation, comparison to benchmarks
1 Data adjusted for splits and stock dividends.
3 Close price on the filing date of Eli Lilly & Co.’s Annual Report.
4 FCFE per share = FCFE ÷ No. shares of common stock outstanding
= ÷ =
5 P/FCFE = Share price ÷ FCFE per share
= ÷ =
|P/FCFE||Price to free cash flow to equity is cash valuation indicator of stockholders’ equity.||Eli Lilly & Co.’s P/FCFE ratio declined from 2016 to 2017 but then increased from 2017 to 2018 exceeding 2016 level.|